This phase II trial studies how well Gallium-68 prostate specific membrane antigen positron emission tomography (PET) work in diagnosing patients with thyroid cancer. Diagnostic procedures, such as 68Ga-PSMA PET, may more accurately diagnose thyroid cancer and find out how far the disease has spread.
Study sponsor and potential other locations can be found on ClinicalTrials.gov for NCT03463889.
PRIMARY OBJECTIVES:
I. To determine the feasibility and utility of Gallium Ga 68-labeled PSMA-11 (68Ga-PSMA) PET imaging in patients with thyroid cancer.
SECONDARY OBJECTIVES:
I. To assess the correlation between targeted molecular uptake of 68Ga-PSMA PET in thyroid cancer compared to areas identified as tumor by radioiodine uptake (in well-differentiated cancers) or fludeoxyglucose F-18 (18F-FDG) uptake (in poorly differentiated and/or radioiodine-negative cancers).
II. To determine and compare the sensitivity and specificity of 68Ga-PSMA PET to (18F-FDG) PET and/or radioiodine scintigraphy.
EXPLORATORY OBJECTIVES:
I. To determine if 68Ga-PSMA PET uptake is related to tumor differentiation and PSMA staining in tissue pathology when available.
II. To determine the correlation between standardized uptake value maximum (SUVmax) of target thyroid cancer lesions on 68Ga-PSMA PET and serum thyroglobulin levels.
OUTLINE:
Patients receive 68Ga-PSMA intravenously (IV) over 1-2 minutes and then undergo PET/magnetic resonance imaging (MRI) 50-80 minutes after injection. Patients may undergo a second PET/MRI 2-6 months after completion of first scan.
Lead OrganizationUniversity of California San Francisco
Principal InvestigatorRobert Flavell
